BMS-641988

Experimental drug for prostate cancer

{{Drugbox | verifiedfields = changed | verifiedrevid = 477002123 | IUPAC_name = (2S)-N-[(1R)-1-Cyano-2-phenylethyl]-3-(4-cyanophenyl)-2-[[4-(trifluoromethyl)phenyl]methylamino]propanamide | image = BMS-641988_structure.png | width = 250 | CAS_number = 1001350-96-4 | PubChem = 16054624 | ChemSpiderID = 17286447 | UNII = 9X0X8R0X0Q | KEGG = D09992 | ChEMBL = 2103874 | C=28 | H=24 | F=3 | N=3 | O=1 | smiles = C1=CC=C(C=C1)C(C#N)C(C(=O)NC(C2=CC=C(C=C2)C#N)CNC3=CC=C(C=C3)C(F)(F)F)N }}

BMS-641988 is an investigational drug developed by Bristol-Myers Squibb for the treatment of prostate cancer. It is a nonsteroidal antiandrogen that acts as an antagonist of the androgen receptor.

Mechanism of Action

BMS-641988 functions by inhibiting the activity of the androgen receptor, a critical driver of prostate cancer cell growth. By blocking this receptor, BMS-641988 prevents the binding of androgens, such as testosterone and dihydrotestosterone, which are necessary for the proliferation of prostate cancer cells.

Development and Clinical Trials

BMS-641988 was developed as part of a series of compounds aimed at improving the treatment of castration-resistant prostate cancer (CRPC). Preclinical studies demonstrated its potential efficacy in inhibiting tumor growth. However, during clinical trials, concerns about its safety profile, particularly regarding seizure risk, led to the discontinuation of its development.

Pharmacokinetics

The pharmacokinetic profile of BMS-641988 includes its absorption, distribution, metabolism, and excretion characteristics. It was designed to have a favorable oral bioavailability and a half-life suitable for once-daily dosing. The drug undergoes hepatic metabolism, primarily via the cytochrome P450 enzyme system.

Safety and Efficacy

While BMS-641988 showed promise in preclinical models, its clinical development was halted due to adverse effects observed in early-phase trials. The primary concern was the occurrence of seizures, which posed significant safety risks to patients.

Related Pages

• Prostate cancer
• Androgen receptor
• Nonsteroidal antiandrogen
• Castration-resistant prostate cancer
• Bristol-Myers Squibb